AstraZeneca and MSD’s Lynparza (olaparib) Receive European Commission’s Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and MSD’s Lynparza (olaparib) Receive European Commission’s Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

Shots:

  • The approval is based on P-III SOLO-1 study result assessing Lynparza (300mg, bid) as a maintenance monothx. vs PBO in 391 patients in ratio (2:1) with BRCA-mutated advanced ovarian cancer following 1L platinum-based CT
  • The P-III SOLO results demonstrated that 60% of patients showed disease-free progression after three yrs. of treatment and only 27% in patients receiving placebo
  • Lynparza is a PARP inhibitor, act by blocking DNA damage response (DDR) in cells/tumors and has received approval in 60+ countries including the US, EU as 1L maintenance treatment for BRCAm advanced ovarian cancer and in 40+ countries for germline BRCAm HER2-negative metastatic breast cancer

Click here to read full press release/ article | Ref: AstraZeneca | Image: Coroflot